Menu Search
Equities

Utah Medical Products Inc

UTM:FRA

Utah Medical Products Inc

Actions
  • Price (EUR)63.00
  • Today's Change-0.50 / -0.79%
  • Shares traded50.00
  • 1 Year change-25.88%
  • Beta--
Data delayed at least 15 minutes, as of Apr 24 2024 07:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Utah Medical Products, Inc. is engaged in the business of producing medical services. The Company markets a range of medical devices used in critical care areas, especially the neonatal intensive care unit (NICU), the labor and delivery (L&D) department and the women's health center in hospitals, as well as medical devices sold to outpatient clinics and physician's offices. The Company's products include BT-CATH, CVX-RIPE, CVX-RIPE, MUC-X, AROM-CO, DISPOSA-HOOD, DELTRAN PLUS, EPITOME and OptiMicro Electrosurgical Devices, Filshie Clip System, PATHFINDER PLUS, SUPRAPUBIC CATHETERIZATION, LIBERTY System, ENDOCURETTE, and LUMIN. BT-CATH is a uterine balloon tamponade catheter for controlling severe postpartum hemorrhage. MUC-X is an aspiration device used immediately after birth to clear neonatal respiratory passages and reduce exposure to potential infections. AROM-CO is a finger cover with a prong designed to rupture maternal membranes with less patient pain and anxiety.

  • Revenue in USD (TTM)50.22m
  • Net income in USD16.64m
  • Incorporated1978
  • Employees169.00
  • Location
    Utah Medical Products Inc7043 S 300 WestMIDVALE 84047United StatesUSA
  • Phone+1 (801) 566-1200
  • Fax+1 (801) 566-7305
  • Websitehttp://www.utahmed.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.